IL-6, as a marker of inflammation, has been linked with proteome changes consistent with an exacerbation of the acute phase response in COVID-19 patients [29] and was successfully used as an adjunctive target therapy in critically ill patients [30]. This evidence concerns the gene IL6 and COVID-19.